Aldesleukin by Iovance Biotherapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval

Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).

Shorter Antibiotic Course Noninferior for UTI Recurrence in Kids

Five days of oral antibiotic treatment for febrile urinary tract infections (UTIs) in kids was noninferior to the standard 10-day course, the randomized controlled STOP

December 27, 2023

FDA approves Medtronic high blood pressure device despite a negative advisory panel vote

The Food and Drug Administration has approved a Medtronic device to lower blood pressure, the company announced Friday evening. The decision comes after an advisory

November 18, 2023

Before Stroke Thrombectomy, Keep the Bed Flat, Trial Says

PHOENIX — For large vessel occlusion (LVO) acute ischemic stroke patients planned for mechanical thrombectomy, bed positioning made a big difference in clinical worsening, the

February 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.